The Role of G Protein Activation in the Toxicity of Amyloidogenic Abeta -(1-40), Abeta -(25-35), and Bovine Calcitonin*

Dawn L. Rymer and Theresa A. GoodDagger

From the Department of Chemical Engineering, Texas A & M University, College Station, Texas 77843-3122

Received for publication, July 3, 2000, and in revised form, October 30, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

More than 16 different proteins have been identified as amyloid in clinical diseases; among these, beta -amyloid (Abeta ) of Alzheimer's disease is the best characterized. In the present study, we performed experiments with Abeta and calcitonin, another amyloid-forming peptide, to examine the role of G protein activation in amyloid toxicity. We demonstrated that the peptides, when prepared under conditions that promoted beta -sheet and amyloid fibril (or protofibril) formation, increased high affinity GTPase activity, but the nonamyloidogenic peptides had no discernible effects on GTP hydrolysis. These increases in GTPase activity were correlated to toxicity. In addition, G protein inhibitors significantly reduced the toxic effects of the amyloidogenic Abeta and calcitonin peptides. Our results further indicated that the amyloidogenic peptides significantly increased GTPase activity of purified Galpha o and Galpha i subunits and that the effect was not receptor-mediated. Collectively, these results imply that the amyloidogenic structure, regardless of the actual peptide or protein sequence, may be sufficient to cause toxicity and that toxicity is mediated, at least partially, through G protein activation. Our abilities to manipulate G protein activity may lead to novel treatments for Alzheimer's disease and the other amyloidoses.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The amyloidoses are complex, multiform disorders characterized by the polymerization and aggregation of normally innocuous and soluble proteins or peptides into extracellular insoluble fibrils. More than 16 biochemically unique proteins, including transthyretin, alpha -synuclein, calcitonin, beta 2-macroglobulin, gelsolin, amylin, and beta -amyloid, have been isolated as the fibrillar components of disease-associated amyloid deposits (1-5). These proteins share no conserved primary structural motives or other structural homologies, but their fibrils all possess some common structural features (3, 6, 7). All amyloid fibrils contain beta -sheet structures in which the polypeptide chains are orthogonally aligned in the fibril directions (8-10). With Congo Red staining, amyloids show a green birefringence under polarized light, and under electron microscopy, their morphology consists of bundles of nonbranching, long filaments about 5-12 nm wide (4, 5, 11).

The most characterized amyloid-forming peptide is beta -amyloid (Abeta )1 of Alzheimer's disease. The toxicity of Abeta has been directly linked to structure and amyloid content. In an aggregated state (containing fibrils, protofibrils, and low molecular weight intermediates), Abeta has been consistently shown to be toxic to neurons in culture (12-18). Although there is some disagreement as to the exact structure of the aggregated species associated with toxicity, whether it be a protofibril (14, 19), a diffusible, nonfibrillar ligand (20), or some other low molecular weight intermediate (19), toxicity is associated with peptide structures that are part of the aggregation pathway associated with amyloid formation. In addition, Abeta neurotoxicity has been shown to be attenuated by Congo Red and rifampicin, which bind to and selectively inhibit the formation of Abeta amyloid fibrils (21-24). Clearly, all of these observations imply a causal link between Abeta fibril formation and neurodegeneration.

Various research groups have hypothesized potential molecular mechanisms of beta -amyloid toxicity, but there is no consensus. Cellular responses to Abeta that have been postulated to result in toxicity encompass destabilization of calcium homeostasis, membrane depolarization, increased vulnerability to excitotoxins, increased membrane permeability due to free radical generation, blockage or functional loss of potassium channels, and direct disruption of membrane integrity (17, 18, 25-36). The preceding plethora of observed biochemical responses to Abeta suggests that perhaps a more common, fundamental pathway is initially being activated and that this pathway subsequently diverges to produce many unique intracellular responses.

Analogous to Abeta , calcitonin is another model amyloid peptide associated with medullary carcinoma of the thyroid (37-43). The fibrils of human calcitonin have also been shown to be neurotoxic (44-46), suggesting that the amyloidoses may possess a shared mechanism of toxicity related to their secondary and macromolecular structures.

To explore if a common, fundamental mechanism of toxicity exists in the amyloidoses, we examined the structure-function relationships of several synthetic Abeta sequences, Abeta -(1-40), Abeta -(25-35), Abeta -(1-16), and bovine calcitonin. We were able to manipulate the secondary and macromolecular structures of these peptides to produce stable amyloid and nonamyloid structures. With these model systems, we demonstrated that the peptides in an amyloid state (with high beta -sheet content and the ability to bind Congo Red) altered G protein activity associated with both cell membrane extracts and purified Galpha subunits. We showed that the abilities of the peptides to induce GTPase activation were correlated with their toxicities, and the neurotoxicities of the peptides were attenuated by specific and nonspecific GTPase inhibitors. In addition, we demonstrated that significant GTPase activities were still induced even when the cell surface receptors were removed with a nonspecific protease. These results suggest that G protein activation, possibly induced via a protein-membrane interaction, plays an important role in the toxicity of Abeta and other amyloid-forming proteins.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Abeta -(1-40), Abeta -(25-35), and Abeta -(1-16) were purchased from BIOSOURCE International (Camarillo, CA), and bovine calcitonin was obtained from Sigma. ATP and GTP were purchased from Aldrich, and [gamma -32P]GTP was from ICN Biochemicals (Irvine, CA). Suramin and Pronase were acquired from Calbiochem and Roche Molecular Biochemicals, respectively. Cell culture reagents were purchased from Life Technologies, Inc. Purified 1,2-dipalmytoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol were obtained from Avanti Polar Lipids (Alabaster, AL). The XK16/70 column and Superfine Sephadex G-50 for size exclusion were acquired from Amersham Pharmacia Biotech. Purified Go and Gi alpha  subunits and epinephrine were purchased from Calbiochem. All other chemicals, unless otherwise specified, were obtained from Sigma.

Abeta Peptide Preparation-- The Abeta peptides were prepared analogously to established methods in the toxicity and structural literature for forming beta -sheet structures and fibril formations (47-50). Stock solutions of 10 mg/ml were prepared by dissolving the Abeta peptides in 0.1% (v/v) trifluoroacetic acid in water. After incubating for 1 h at 25 °C, the peptide stock solutions were diluted to concentrations of 0.5 mg/ml in sterile phosphate-buffered saline (PBS) (0.01 M NaH2PO4, 0.15 M NaCl, pH 7.4) with antibiotics. These solutions were rotated on a model RD4524 rotator (Glas-col, Terre Haute, IN) at 60 rpm at 25 °C for 24 h. The peptides were then diluted to final concentrations of 20 µM in sterile medium and rotated for an additional 24 h prior to being added to the culture wells or plates for the toxicity and GTP studies.

The Structural Characterization and Preparation of Bovine Calcitonin-- Bovine calcitonin was directly dissolved in various solvents and buffers at concentrations of 40 and 80 µM. CD measurements of the solutions were recorded 2-24 h later on a model 62DS spectrometer (Aviv Instruments, Lakewood, NJ) at 25 °C using a bandwidth of 1.0 nm, a step interval of 0.5 nm, and an averaging time of 2 s. A 0.01-cm quartz cell was used for the far-UV (190-250 nm) measurements. The instrument was calibrated using D(+)-10-camphorsulfonic acid. Three scans each of duplicate samples were measured and averaged. Control buffer and solvent scans were run in duplicate, averaged, and then subtracted from the sample spectra. Spectra were analyzed using the secondary structural parameters reported by Chang (51) to ascertain the sample percentages of alpha -helix, beta -sheet, beta -turn, and random-coil.

To assess the presence of amyloid fibrils in the calcitonin solutions, Congo Red binding studies were performed. Congo Red dye was dissolved in PBS to a final concentration of 112 µM. Congo Red absorbances of the calcitonin solutions and free dye controls were determined by adding Congo Red to a final concentration of 12 µM and acquiring spectral measurements from 300 to 900 nm at 25 °C on a model 420 UV-visible spectrophotometer (Spectral Instruments, Tucson, AZ) (52, 53). Both the calcitonin solutions and the control solutions were allowed to interact with Congo Red for 1 h prior to recording their spectra. Congo Red difference spectra were calculated by subtracting the free dye absorbance from the calcitonin-dye absorbances.

Finally, bovine calcitonin was prepared in the following manner for the toxicity and GTP studies. Calcitonin was dissolved at a concentration of 1.5 mg/ml in either deionized water or a solution of 5 mM CaCl2 and 1 mM MgCl2 in water. These solutions were rotated at 60 rpm at 25 °C for 24 h. Then the calcitonin solutions were diluted to 40 and 80 µM with sterile medium and rotated for an additional 24 h prior to being added to the culture wells or plates for the toxicity and GTP studies.

Cell Culture-- Human neuroblastoma SH-SY5Y cells (a gift of Dr. Evelyn Tiffany-Castiglioni, College of Veterinary Medicine, Texas A & M University, College Station, TX) were cultured in a humidified 5% (v/v) CO2/air environment at 37 °C in minimum Eagle's medium supplemented with 10% (v/v) fetal bovine serum, 3 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, and 2.5 µg/ml amphotericin B (fungizone). Likewise, rat pheochromocytoma PC12 cells (ATCC, Manassas, VA) were cultured in RPMI medium supplemented with 10% (v/v) horse serum, 5% (v/v) fetal bovine serum, 3 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, and 2.5 µg/ml fungizone in a 5% (v/v) CO2/air environment at 37 °C. For the GTP studies, cells were plated at densities ranging from 2.5 to 4 million cells in 35-mm tissue culture dishes. For the viability assays, cells were plated at a density of 1 × 105 cells/well in 96-well plates. During both the GTP and viability studies, the peptides were added to the cells 24 h after plating.

Membrane Preparation for the GTPase Assay-- After incubation with the peptides or controls for 30 min at 37 °C, the PC12 or SH-SY5Y membranes were isolated using the widely accepted method of Seifert and Schultz (54). Cells were harvested with a cell scraper and collected by centrifugation (1600 × g, 4 °C, 20 min). Subsequently, they were washed with a buffer consisting of 10 mM triethanolamine (TEA) and 140 mM NaCl (pH 7.4) and disrupted by nitrogen cavitation in a 50 mM KH2PO4 buffer with 100 mM NaCl, 3 mM EDTA, and 15 mM beta -mercaptoethanol (pH 7.0). The nuclear portion of the cells was removed by a short centrifugation (1000 × g, 4 °C, 2 min), and membrane sedimentation was attained with a long centrifugation (15,000 × g, 4 °C, 60 min). The resulting membrane pellet was suspended in a 10 mM TEA/HCl buffer (pH 7.4), and the total membrane protein content was measured with the BCA assay (55).

GTPase Assay-- The GTPase activities of the PC12 and SH-SY5Y membranes were assessed similarly to procedures described previously (56-60). Reaction mixtures of 100 µl consisted of 0.4 µM [gamma -32P]GTP (0.5 µCi/tube), 0.5 mM MgCl2, 0.1 mM EGTA, 0.1 mM ATP, 1 mM AMP-PNP, 5 mM creatine phosphate, 40 µg of creatine kinase, 1 mM dithiothreitol, and 0.2% (w/v) bovine serum albumin in 50 mM TEA/HCl (pH 7.4). Following a 5-min preincubation period at 25 °C, the reaction was initiated by the addition of 5-8 µg of membrane protein. After 15 min at 25 °C, the reaction was stopped by the addition of 800 µl of a 20 mM KH2PO4 buffer (4 °C, pH 7.0) containing 5% (w/v) activated charcoal. The released 32Pi was separated from the nucleotide-bound phosphate by centrifugation (15000 × g, 4 °C, 20 min), and 100 µl of the supernatant was counted on a Topcount Microplate Scintillation Counter (Packard Instrument Co.).

Low affinity or nonspecific GTPase activity was measured by adding excess unlabeled GTP (50 µM) to the aforementioned reaction mixture and conducting the reaction as described. Specific high affinity GTPase activity was calculated as the difference between the total GTPase activity in the absence of unlabeled GTP and the low affinity GTPase activity.

Pronase Experiments-- Pronase studies were conducted analogously to established procedures (61-63). Pronase at a concentration of 3 mg/ml in serum-free RPMI was incubated with the plated PC12 cells for 1 h at 4 °C. The cells were harvested with a cell scraper and collected by centrifugation (1600 × g, 4 °C, 20 min). Then the cells were thoroughly washed with PBS and centrifuged again (1600 × g, 4 °C, 20 min) prior to the addition of the peptides or controls for the GTPase assays. For the epinephrine control, 200 µM epinephrine in serum-free RPMI was incubated with these Pronase-treated PC12 cells for 30 min prior to the membrane isolation step.

MTT Reduction Assay-- SH-SY5Y and PC12 cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. MTT is reduced by viable cells to form blue formazan crystals, and inhibition of this reaction is indicative of cellular redox alterations that could result in toxicity (64). The peptides were incubated with the SH-SY5Y and PC12 cells for 24 h, after which time MTT reduction was assessed. MTT was added to the culture medium to yield a final concentration of 0.5 mg/ml. The cells were allowed to incubate with the MTT for 4 h in a CO2 incubator after which time 100 µl of a 5:2:3 N,N-dimethylformamide/SDS/water solution (pH 4.7) was added to dissolve the formed formazan crystals. After 18 h of incubation in a humidified CO2 incubator, the results were read using an Emax Microplate reader at 585 nm (Molecular Devices, Sunnyvale, CA). Viability is reported relative to control cells unexposed to the peptides.

GTPase and Toxicity Inhibition-- Pertussis toxin (PT) (100 ng/ml), GDPbeta S (600 µM), and suramin (20 µM) were incubated with the PC12 and SH-SY5Y cells for 24, 3, and 3 h, respectively, at 37 °C prior to the peptide additions for the GTPase or toxicity assays. The peptide solutions for these assays also contained the same inhibitors at the same concentrations. Control cells were treated identically except for the presence of peptide.

Reconstitution of Galpha o and Galpha i Vesicles-- Vesicles consisted of 82% (w/w) DPPC and 18% (w/w) cholesterol, and they were prepared by mixing the DPPC and cholesterol in chloroform and evaporating off the solvent under nitrogen at 50 °C in a 421-4000 Micro Rotary Evaporator (Labconco, Kansas City, MO). 20 mM NaHepes (pH 8.0) containing 0.4% (w/v) deoxycholate and 0.04% (w/v) cholate was then added to suspend the lipid film, producing a final lipid concentration of 1 mg/ml. The resulting DPPC/cholesterol suspension was sonicated for 10 min. Subsequently, 1.2 volumes of these DPPC/cholesterol vesicles were combined with 0.6 volume of Galpha o or Galpha i in a 10 mM NaHepes buffer (pH 8.0) containing 1 mM EDTA, 0.1 mM dithiothreitol, and 0.1% (v/v) Genapol. This mixture was gel-filtered using an ÄKTA Explorer (Amersham Pharmacia Biotech) with Sephadex G-50 in a XK16/70 column at a flow rate of 0.5 ml/min according to procedure of Pedersen and Ross (65). The elution buffer consisted of 20 mM NaHepes buffer (pH 8.0), 1 mM EDTA, 1 mM dithiothreitol, 0.1 M NaCl, and 2 mM MgCl2.

Galpha GTPase Assay-- GTPase activity was assayed by incubating the Galpha o or Galpha i vesicles (5 µl; 75 fmol of Galpha o or Galpha i) at 30 °C in a total volume of 100 µl containing 50 mM NaHepes (pH 8.0), 1 mM EDTA, 1 mM dithiothreitol, 0.1 M NaCl, 2 mM MgCl2, 0.1 mM adenosine AMP-PNP, 0.1 mM ascorbic acid, and 0.1 µM [gamma -32P]GTP. After the specified time, the reaction was stopped by the addition of 250 µl of a 50 mM NaH2PO4 buffer (4 °C, pH 7.0) with 5% (w/v) activated charcoal and rapid chilling. The mixture was centrifuged (1200 × g, 4 °C, 10 min), and the [32P]Pi in the supernatant (200 µl) was counted on a Topcount Microplate Scintillation Counter (Packard Instrument Co.).

Statistical Analysis-- The significance of results was determined using a Student's t test on n independent measurements, where n is specified in the figure legend. Unless otherwise indicated, significance was taken as p < 0.05.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Peptide Secondary and Macromolecular Structures-- The structures of the Abeta peptides under the employed solvation conditions have been well characterized and were not re-examined. Under these conditions, Abeta -(1-40) and Abeta -(25-35) have been shown to be amyloidogenic (containing fibrils and protofibrils) and to contain extensive beta -sheet structures, whereas Abeta -(1-16) has been demonstrated to be nonamyloidogenic and predominantly random coil (47-50).

Because the solution structures of bovine calcitonin are not as well documented, we identified conditions that promoted the formation of beta -sheet structure and amyloid using CD spectroscopy and Congo Red binding assays. As determined by CD (Fig. 1A), both 40 and 80 µM bovine calcitonin in water containing 5 mM CaCl2 and 1 mM MgCl2 adopted structures with ~55 ± 10% beta -sheet and only 15 ± 10% alpha -helix. Incubating the peptide in deionized water alone at these same concentrations (Fig. 1A) produced structures devoid of beta -sheet character with 95 ± 10% alpha -helical contents. As depicted by Congo Red difference spectra (Fig. 1B), the 40 and 80 µM water solutions of bovine calcitonin with 5 mM CaCl2 and 1 mM MgCl2 significantly bound and shifted the spectral properties of Congo Red, indicating the formation of amyloid. The zero difference spectrum of the peptide in deionized water indicated an absence of Congo Red binding and substantial amyloid fibril formation (spectrum not shown).



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 1.   The structural characterization of bovine calcitonin. A, representative CD spectra illustrating that 80 µM calcitonin dissolved in deionized water (black-square) was predominantly alpha -helical, whereas both 40 (open circle ) and 80 µM () calcitonin dissolved in water containing 5 mM CaCl2 and 1 mM MgCl2 were enriched in beta -sheet character. B, absorbance difference spectra for Congo Red indicated that 40 (open circle ) and 80 µM () calcitonin dissolved in water with divalent cations were amyloidogenic.

GTPase Activity-- By using Abeta -(1-40), Abeta -(25-35), and bovine calcitonin in water with 5 mM CaCl2 and 1 mM MgCl2 as models of peptides with amyloidogenic structures and Abeta -(1-16) and bovine calcitonin in deionized water as models of peptides without amyloidogenic structures, we examined the relationship between peptide structure and GTPase activity. We found that the rate of high affinity GTP hydrolysis in PC12 membranes increased by 31 ± 12% on average with exposure to the peptides containing extensive beta -sheet and amyloid contents relative to the rate of hydrolysis of control cells unexposed to peptides (Fig. 2A). In all cases, the increases in GTPase activity were significant relative to the control cells (p < 0.001). The rates of GTP hydrolysis were significantly greater for Abeta -(25-35) and 80 µM calcitonin (p < 0.001), the two peptides with the greatest amyloid content, than for Abeta -(1-40) and 40 µM calcitonin, suggesting that the extent of macromolecular structure influences the process. Similarly, Abeta -(1-16) and bovine calcitonin in deionized water, the peptides devoid of amyloid and beta -sheet structures, did not significantly alter the GTPase activities of the PC12 cells relative to untreated controls (Fig. 2A) (p > 0.2).



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   The GTPase activities of the Abeta and calcitonin peptides as a function of their solution structures. PC12 (A) and SH-SY5Y (B) cells were exposed to the peptides or controls for 30 min at 37 °C in a humidified 5% CO2 environment prior to the GTPase membrane isolation step. The means ± S.D. of 3-8 determinations are depicted. Only the peptides with significant beta -sheet and amyloid contents increased the high affinity GTP hydrolysis. *, **, and *** indicate that the increases in the rates of hydrolysis relative to the untreated control cells were significant at p < 0.002, p < 0.0005, and p < 0.0001, respectively.

To ensure that the observed phenomena were not isolated to PC12 cells, we examined the GTPase activities of SH-SY5Y membranes exposed to bovine calcitonin. We found similar trends to those observed with the PC12 cells (Fig. 2B). The rate of GTP hydrolysis increased from 16.0 ± 0.5 pmol/mg/min for the control cells to 23.8 ± 0.6 and 18.7 ± 0.6 pmol/mg/min for the cells exposed to 80 and 40 µM bovine calcitonin in water with 5 mM CaCl2 and 1 mM MgCl2, respectively (p < 0.002). The nonamyloidogenic 80 µM calcitonin in water did not significantly alter GTPase activity relative to the controls (16.0 ± 0.3 pmol/mg/min, p > 0.4).

Toxicity-- In parallel to the GTPase activity experiments, we examined the relationship between peptide structure and toxicity using our model peptides. As seen in Fig. 3, A and B, analogous to our GTPase results, we found that exposure to the peptides containing extensive beta -sheet and amyloid contents resulted in significant PC12 (Fig. 3A) and SH-SY5Y (Fig. 3B) cell toxicity (p < 0.001). Conversely, Abeta -(1-16) and bovine calcitonin in deionized water, the peptides devoid of amyloid and beta -sheet structures, did not significantly alter cell viability relative to untreated controls (p > 0.2).



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3.   The toxicities of the Abeta and calcitonin peptides as a function of their solution structures. The abilities of the PC12 (A) and SH-SY5Y (B) cells to reduce MTT were taken as indications of cell viability. The data are reported as the percentage of the MTT reduced by the cells treated with the Abeta and calcitonin solutions for 24 h relative to the MTT reduced by the cells untreated with these solutions. The means ± the S.D. of 8-10 determinations are depicted. The Abeta -(1-40), Abeta -(25-35), and calcitonin/salt solutions, which contained substantial amyloid contents and beta -sheet structures, always significantly inhibited the ability of the cells to reduce MTT (*, p < 0.001), but the nonamyloidogenic bovine calcitonin in deionized water and Abeta (1-16) did not significantly alter cell viability (p > 0.2).

GTPase Inhibition-- To identify the family or families of G proteins activated by the amyloid-forming peptides, we investigated the effects of GDPbeta S and suramin, two nonspecific G protein inhibitors (66-73), and PT, a specific inhibitor of the Gi and Go families of G proteins (74-78). As illustrated in Fig. 4A, GDPbeta S, suramin, and PT were each able to inhibit significantly the increases in GTP hydrolysis observed in PC12 membranes exposed to the amyloidogenic Abeta -(1-40), Abeta -(25-35), and bovine calcitonin (p < 0.005). Analogously, the inhibitors significantly reduced the rate of GTP hydrolysis induced by amyloidogenic calcitonin in membranes from SH-SY5Y cells (Fig. 4B, p < 0.001).



View larger version (48K):
[in this window]
[in a new window]
 
Fig. 4.   The effect of pharmacological agents on GTPase activity. G protein inhibitors consistently reduced the high affinity GTP hydrolysis of the PC12 (A) and SH-SY5Y (B) cells caused by the amyloidogenic Abeta peptides and bovine calcitonin. The means ± S.D. of 3-6 determinations are depicted. Untreated PC12 or SH-SY5Y cells were exposed to the amyloids for 30 min at 37 °C in a humidified 5% CO2 environment in the absence of all pharmacological agents. Treated PC12 or SH-SY5Y cells were preincubated with 100 ng/ml PT, 20 µM suramin, or 600 µM GDPbeta S for 24, 3, and 3 h, respectively, at 37 °C in a humidified 5% CO2 environment. Following this preincubation, treated cells were exposed to amyloidogenic peptide solutions containing the same inhibitors for 30 min at 37 °C in a humidified 5% CO2 environment prior to the GTPase membrane isolation step. PT (open bars), suramin (diagonally striped bars), and GDPbeta S (cross-hatched bars) significantly reduced membrane GTPase activity relative to the cells exposed to the amyloids in the absence of these compounds (solid bars). * and ** indicate that the decreases in the rates of hydrolysis relative to the untreated cells were significant at p < 0.005 and p < 0.001, respectively.

Pronase Experiments-- To ascertain if the peptide-induced increases in GTPase activity were mediated through something other than a peptide-receptor interaction, GTPase studies were performed with PC12 cells treated with Pronase. Pronase is a nonspecific protease that has been documented to remove cell surface receptors (61-63). As shown in Fig. 5, GTP hydrolysis still increased significantly in the presence of the amyloidogenic bovine calcitonin, Abeta -(1-40), and Abeta -(25-35) relative to control cells treated with Pronase but unexposed to the peptides (p < 0.003). The rates of GTP hydrolysis for the Pronase-treated cells incubated with Abeta -(1-40), Abeta -(25-35), and 80 µM bovine calcitonin in water with divalent cations were increased by 9, 17, and 25% respectively, compared with the Pronase-treated control cells. We also examined the GTP hydrolysis of Pronase-treated cells with the nonamyloidogenic Abeta -(1-16) and bovine calcitonin in deionized water (Fig. 5). As expected, these peptides did not significantly alter GTPase activity relative to the control cells (p > 0.15).



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   The effect of Pronase-treatment on GTPase activity. PC12 cells were incubated with 3 mg/ml Pronase in serum-free RPMI media for 1 h at 4 °C. After washing and centrifugation, the Pronase-treated cells were replated with the peptide solutions or controls and incubated for 30 min at 37 °C in a humidified 5% CO2 environment prior to the GTPase membrane isolation step. The means ± the S.D. of 3-5 determinations are depicted. Only the amyloidogenic peptides significantly increased GTP hydrolysis relative to the Pronase-treated control cells. The absence of increased GTP hydrolysis in the presence of epinephrine indicated that the Pronase treatment effectively removed the cell surface receptors. * and ** indicate that the increases in the GTPase activity relative to the Pronase-treated control cells were significant at p < 0.003 and p < 0.0001, respectively.

To demonstrate the effectiveness of Pronase treatment at receptor removal, we incubated cells with 200 µM epinephrine and then measured the rate of GTP hydrolysis. Without Pronase treatment, 200 µM epinephrine increased the rate of GTP hydrolysis in PC12 cells by 100% (data not shown). However, as seen in Fig. 5, after Pronase removal of cell receptors, incubation with epinephrine did not significantly alter the rate of GTP hydrolysis in the Pronase-treated cells relative to Pronase-treated control cells (p > 0.3). These results indicate that the cell receptors had been effectively removed by the Pronase.

Galpha o and Galpha i GTPase Assays-- To demonstrate more specifically that the peptides were interacting with heterotrimeric G proteins, we performed GTPase assays with lipid vesicles containing purified Galpha o and Galpha i subunits (Fig. 6, A and B). Analogous to the cell membrane GTP results, the amyloidogenic Abeta -(1-40), Abeta -(25-35), and 80 µM bovine calcitonin significantly increased GTPase activity in both the Galpha o and Galpha i vesicles (p < 0.001). In contrast, Abeta -(1-16) and bovine calcitonin in deionized water, the peptides devoid of amyloid and beta -sheet structures, did not significantly stimulate GTPase activity in either vesicle system at any of the experimental times. No receptors were included in the Galpha preparations.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 6.   The GTPase activities of the Galpha o vesicles (A) and the Galpha i vesicles (B). The production of 32Pi as a function of time, an indication of GTPase activity, is shown. Vesicles (5 µl; 75 fmol of Galpha o or Galpha i) were incubated at 30 °C for the times shown. The amyloidogenic 20 µM Abeta -(1-40) (open circle ), 20 µM Abeta -(25-35) (black-triangle), and 80 µM bovine calcitonin in water containing 5 mM CaCl2 and 1 mM MgCl2 () stimulated GTPase activity in both the Galpha o and Galpha i vesicles, but the nonamyloidogenic 20 µM Abeta -(1-16) (Delta ) and 80 µM bovine calcitonin in deionized water (black-square) did not significantly affect GTPase activity in either vesicle system at any of the experimental times. Hydrolysis in the absence of vesicles is also shown (black-down-triangle ). The data presented are averages of triplicate determinations that varied by less than 10%, and the standard deviations of the determinations are indicated by error bars where significant. The zero time, zero protein values represent 32Pi contaminating the [gamma -32P]GTP.

Toxicity Inhibition-- To explore if the observed GTPase activity was potentially linked to neurotoxicity, we examined if the GTPase inhibitors attenuated the cell death caused by amyloidogenic bovine calcitonin, Abeta -(1-40), and Abeta -(25-35). GDPbeta S, suramin, and PT each significantly attenuated amyloid-induced PC12 cell toxicity as seen in Fig. 7A (p < 0.0005). Untreated cells exposed to Abeta -(1-40), Abeta -(25-35), and 80 µM bovine calcitonin in water with divalent cations were 52 ± 7% viable on average, but the cells treated with GDPbeta S, suramin, and PT had viabilities of 83 ± 3, 81 ± 3, and 82 ± 4%, respectively. Comparable neuroprotective trends were observed in SH-SY5Y cells (Fig. 7B).



View larger version (76K):
[in this window]
[in a new window]
 
Fig. 7.   The influence of pharmacological agents on cell viability as measured by MTT reduction. The inhibition of G protein activation with PT, GDPbeta S, and suramin attenuated the cell death caused by the amyloidogenic bovine calcitonin, Abeta -(25-35), and Abeta -(1-40) in PC12 (A) and SH-SY5Y cells (B). Untreated PC12 and SH-SY5Y cells were exposed to the peptides for 24 h at 37 °C in a humidified 5% CO2 environment in the absence of all pharmacological agents. Treated PC12 or SH-SY5Y cells were preincubated with 100 ng/ml PT, 20 µM suramin, or 600 µM GDPbeta S for 24, 3, and 3 h, respectively, at 37 °C in a humidified 5% CO2 environment. Following this preincubation, treated cells were then exposed to amyloidogenic peptide solutions containing the same inhibitors for 24 h at 37 °C in a humidified 5% CO2 environment cells. The data are reported as the percentage of the MTT reduced by the cells incubated with the peptides alone or with the peptides and inhibitors relative to the MTT reduced by control cells unexposed to the peptides. The means ± S.D. of 8 determinations are presented. In the absence of pharmacological reagents, exposure to the amyloid-forming peptides led to a significant reduction in cell survival relative to the control cells (p < 0.0001). Incubation of the PC12 and SH-SY5Y cells with PT (open bars), suramin (diagonally striped bars), and GDPbeta S (cross-hatched bars) protected them from amyloid-induced cell death relative to untreated cells exposed to the amyloids (solid bars). Incubation of the cells with inhibitors in the absence of the amyloid peptides had no significant effect on cell viability (Control Cells). * and ** indicate that the increases in cell viability relative to the untreated cells exposed to the amyloids were significant at p < 0.0005 and p < 0.0001, respectively.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In previous cell culture studies, the most important predictor of Abeta toxicity was the macromolecular state of the Abeta peptides with only aged or aggregated Abeta peptides (including fibrils, protofibrils, and/or low molecular weight intermediates) consistently eliciting toxic responses (12-18). Additionally, both the L- and D-enantiomers of Abeta exhibited nearly identical structural characteristics and induced similar levels of toxicity, implying that Abeta neurotoxicity was mediated by Abeta fibril features instead of any stereoisomer-specific interactions (79). Compounds such as Congo Red, rifampicin, and recognition peptides that bind to and/or inhibit the formation of amyloid fibrils have also been shown to attenuate the toxicity of Abeta , further establishing the causal link between Abeta structure and function (21-24, 64, 80, 81).

Since the neurotoxic effects of Abeta peptides appear to be linked to peptide structures associated with aggregation and amyloid fibril formation, any plausible molecular mechanism of Abeta toxicity should also demonstrate structural dependence. Our cell membrane and purified subunit data, which suggest that the Abeta toxicity is mediated through a pathway involving peptide-induced G protein activation, possess the required structural specificity. We found that the GTPase activities associated with PC12 membranes and Galpha o and Galpha i vesicles only increased with exposure to the peptides containing extensive beta -sheet and amyloid contents, Abeta -(1-40) and Abeta -(25-35). The nontoxic and nonaggregated Abeta -(1-16) produced no discernible effects on the GTPase activities of the PC12 membranes or the Galpha o and Galpha i vesicles.

Ample evidence exists that suggests that G protein activation and other signal transduction events such as phospholipase D and adenylate cyclase activation may be associated with the biological activity of Abeta (82-84). Also, the reported changes in K+ and Ca2+ ion channel activity and changes in calcium homeostasis are all consistent with GTPase activation being an early event in the mechanism of action of Abeta (26, 30, 85, 86). However, in very few of these studies has anyone shown the relationship between the biological activity and the structure of the peptide, which is essential in establishing the connection between activity and a toxicity mechanism.

Unlike our results, reports of Abeta -induced barium conductances in N1E-115 neuroblastoma cells (87) and calcium fluxes (85, 88) did not correlate aggregation state of the peptide with activity. When Abeta blockage of the fast-inactivating K+ current was investigated, structure-function relationships were examined, but no structure dependence upon ion channel activity was observed (30). In addition, the data associated with the free radical model of Abeta toxicity such as the ability of Abeta peptides to generate EPR signals were not structure-specific (31).

We suggest that amyloidogenic Abeta -induced G protein activation could be an early step in the molecular level mechanism of Abeta toxicity and that activation of alternative G protein pathways could produce many of the observed diverse cellular responses. For example, in our studies, PT had significant inhibitory effects on GTPase activity and toxicity, indicating that the Gi and Go families of G proteins were being activated (74-78). The results of our purified Galpha o and Galpha i subunit GTPase assays confirm this hypothesis. The amyloidogenic Abeta -(1-40) and Abeta -(25-35) significantly increased the GTPase activity of both the Galpha o and Galpha i subunits. Activation of these particular families of G proteins could account for some of the previous ion channel results because they have been linked to certain K+ and Ca2+ channel modulations (89-93). Our results do not preclude the activation of multiple GTPases, which could result in tremendously diverse intracellular phenomena since G proteins and their effectors have been associated with selective protein phosphorylation, gene transcription, cytoskeletal reorganization, secretion, and membrane depolarization (71, 74, 92, 94-96).

In both our Pronase experiments and in our Galpha o and Galpha i subunit experiments, we demonstrated that the presence of receptors was not necessary for the observed amyloidogenic peptide-induced increases in GTPase activity. In the Pronase-treated cells, few receptors remained, as evidenced by the absence of an epinephrine-induced increase in GTP hydrolysis. Similarly, no receptors were included in the Galpha o and Galpha i subunit preparations. However, in both systems, significant peptide-induced increases in GTPase activity were observed. Nonreceptor mediated GTPase activation has been documented with mastoparan, ethanol, and shear stress (59, 97-99). The discovery that our Abeta GTPase activities may be membrane-mediated is consistent with a number of other previous findings, which imply the importance of Abeta -membrane interactions to neurotoxicity. Abeta has been shown to interact with the lipid bilayer of the plasma membrane, forming cation-selective channels and disrupting ion homeostasis (25, 26). Interaction with the plasma membrane may also influence aggregation and amyloid formation of the peptide (33, 34, 100, 101).

In conjunction with our Abeta GTPase results, our calcitonin results suggest that the amyloidoses may share some common steps in the mechanism of toxicity. Analogous to our Abeta findings, we found that amyloidogenic bovine calcitonin in water containing 5 mM CaCl2 and 1 mM MgCl2 increased cell toxicity and increased GTPase activities associated with PC12 membranes and Galpha o and Galpha i vesicles, whereas the nonamyloidogenic calcitonin in deionized water did not significantly alter cell viability or G protein activities of PC12 membranes or Galpha o and Galpha i vesicles. Amyloidogenic bovine calcitonin increased the GTPase activity in Pronase-treated cells and Galpha o and Galpha i vesicles devoid of receptors, and inhibition of GTPase activation attenuated cell toxicity. These results again suggest the potential importance of protein-membrane interactions to amyloid-mediated toxicity and indicate that GTPase activation is an early step in the toxicity of amyloid-forming peptides.

In conclusion, we demonstrated that Abeta and calcitonin peptides altered G protein activity in a structure-specific manner; only the peptides with extensive beta -sheet and amyloid contents significantly increased GTPase activity. Both Go and Gi activation was observed. At least some of the observed amyloid-induced increases in GTPase activity were not receptor-mediated, pointing to the potential importance of peptide-membrane interactions in the biological activity of the peptides. We demonstrated that the observed increases in G protein activity were linked to neurotoxicity by showing that G protein inhibitors significantly reduced the neurotoxic effects of the amyloidogenic Abeta and calcitonin peptides. These results may help to elucidate the mechanism of toxicity and may lead to novel treatments for the 16 or more diseases associated with amyloid proteins.


    FOOTNOTES

* This work was supported by the National Science Foundation (to T. A. G.) and the Welch Foundation (to D. L. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: 337 Zachry, Dept. of Chemical Engineering, Texas A & M University, College Station, TX 77843-3122. Tel.: 979-845-3413; Fax: 979-845-6446; E-mail: tgood@tamu.edu.

Published, JBC Papers in Press, November 1, 2000, DOI 10.1074/jbc.M005800200


    ABBREVIATIONS

The abbreviations used are: Abeta , beta -amyloid; PBS, phosphate-buffered saline; TEA, triethanolamine; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide; PT, pertussis toxin; GDPbeta S, guanosine 5'-O-(2-thiodiphosphate); DPPC, 1,2-dipalmytoyl-sn-glycero-3-phosphocholine; AMP-PNP, adenosine 5'-(beta ,gamma -imino)triphosphate.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Kelly, J. W. (1996) Curr. Opin. Struct. Biol. 6, 11-17[CrossRef][Medline] [Order article via Infotrieve]
2. Kelly, J. W. (1998) Curr. Opin. Struct. Biol. 8, 101-106[CrossRef][Medline] [Order article via Infotrieve]
3. Lansbury, P. T., Jr. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3342-3344[Free Full Text]
4. Sipe, J. D. (1992) Annu. Rev. Biochem. 61, 947-975[CrossRef][Medline] [Order article via Infotrieve]
5. Sipe, J. D. (1994) Crit. Rev. Clin. Lab. Sci. 31, 325-354[Medline] [Order article via Infotrieve]
6. Kelly, J. W. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 930-932[Free Full Text]
7. Taubes, G. (1996) Science 271, 1493-1495[Medline] [Order article via Infotrieve]
8. Glenner, G. G., and Terry, W. D. (1974) Annu. Rev. Med. 25, 131-135[Medline] [Order article via Infotrieve]
9. Glenner, G. G. (1980) N. Engl. J. Med. 302, 1283-1292[Medline] [Order article via Infotrieve]
10. Glenner, G. G. (1980) N. Engl. J. Med. 302, 1333-1343[Medline] [Order article via Infotrieve]
11. Castano, E. M., and Frangione, B. (1995) Curr. Opin. Neurol. 8, 279-285[Medline] [Order article via Infotrieve]
12. Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., and Teplow, D. B. (1999) J. Biol. Chem. 274, 25945-25952[Abstract/Free Full Text]
13. Howlett, D. R., Jennings, K. H., Lee, D. C., Clark, M. S., Brown, F., Wetzel, R., Wood, S. J., Camilleri, P., and Roberts, G. W. (1995) Neurodegeneration 4, 23-32[CrossRef][Medline] [Order article via Infotrieve]
14. Ward, R. V., Jennings, K. H., Jepras, R., Neville, W., Owen, D. E., Hawkins, J., Christie, G., Davis, J. B., George, A., Karran, E. H., and Howlett, D. R. (2000) Biochem. J. 348, 137-144[CrossRef][Medline] [Order article via Infotrieve]
15. Seilheimer, B., Bohrmann, B., Bondolfi, L., Muller, F., Stuber, D., and Dobeli, H. (1997) J. Struct. Biol. 119, 59-71[CrossRef][Medline] [Order article via Infotrieve]
16. Yankner, B. A., Duffy, L. K., and Kirschner, D. A. (1990) Science 250, 279-282[Medline] [Order article via Infotrieve]
17. Busciglio, J., Yeh, J., and Yankner, B. A. (1993) J. Neurochem. 61, 1565-1568[Medline] [Order article via Infotrieve]
18. Koh, J. Y., Yang, L. L., and Cotman, C. W. (1990) Brain Res. 533, 315-320[CrossRef][Medline] [Order article via Infotrieve]
19. Hartley, D. M., Walsh, D. M., Ye, C. P., Diehl, T., Vasquez, S., Vassilev, P. M., Teplow, D. B., and Selkoe, D. J. (1999) J. Neurosci. 19, 8876-8884[Abstract/Free Full Text]
20. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., and Klein, W. L. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 6448-6453[Abstract/Free Full Text]
21. Burgevin, M. C., Passat, M., Daniel, N., Capet, M., and Doble, A. (1994) Neuroreport 5, 2429-2432[Medline] [Order article via Infotrieve]
22. Lorenzo, A., and Yankner, B. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12243-12247[Abstract/Free Full Text]
23. Sadler, I. I., Smith, D. W., Shearman, M. S., Ragan, C. I., Tailor, V. J., and Pollack, S. J. (1995) Neuroreport 7, 49-53[Medline] [Order article via Infotrieve]
24. Tomiyama, T., Asano, S., Suwa, Y., Morita, T., Kataoka, K., Mori, H., and Endo, N. (1994) Biochem. Biophys. Res. Commun. 204, 76-83[CrossRef][Medline] [Order article via Infotrieve]
25. Arispe, N., Pollard, H. B., and Rojas, E. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10573-10577[Abstract]
26. Arispe, N., Rojas, E., and Pollard, H. B. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 567-571[Abstract]
27. Behl, C., Davis, J. B., Lesley, R., and Schubert, D. (1994) Cell 77, 817-827[Medline] [Order article via Infotrieve]
28. Butterfield, D. A., Hensley, K., Harris, M., Mattson, M., and Carney, J. (1994) Biochem. Biophys. Res. Commun. 200, 710-715[CrossRef][Medline] [Order article via Infotrieve]
29. Butterfield, D. A. (1997) Chem. Res. Toxicol. 10, 495-506[CrossRef][Medline] [Order article via Infotrieve]
30. Good, T. A., Smith, D. O., and Murphy, R. M. (1996) Biophys. J. 70, 296-304[Abstract]
31. Hensley, K., Carney, J. M., Mattson, M. P., Aksenova, M., Harris, M., Wu, J. F., Floyd, R. A., and Butterfield, D. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3270-3274[Abstract]
32. Mattson, M. P., Mark, R. J., Furukawa, K., and Bruce, A. J. (1997) Chem. Res. Toxicol. 10, 507-517[CrossRef][Medline] [Order article via Infotrieve]
33. McLaurin, J., and Chakrabartty, A. (1996) J. Biol. Chem. 271, 26482-26489[Abstract/Free Full Text]
34. McLaurin, J., Franklin, T., Fraser, P. E., and Chakrabartty, A. (1998) J. Biol. Chem. 273, 4506-4515[Abstract/Free Full Text]
35. Pike, C. J., Balazs, R., and Cotman, C. W. (1996) J. Neurochem. 67, 1774-1777[Medline] [Order article via Infotrieve]
36. Simmons, M. A., and Schneider, C. R. (1993) Neurosci. Lett. 150, 133-136[CrossRef][Medline] [Order article via Infotrieve]
37. Berger, G., Berger, N., Guillaud, M. H., Trouillas, J., and Vauzelle, J. L. (1988) Virchows Arch. A Pathol. Anat. Histopathol. 412, 543-551[Medline] [Order article via Infotrieve]
38. Butler, M., and Khan, S. (1986) Arch. Pathol. Lab. Med. 110, 647-649[Medline] [Order article via Infotrieve]
39. Byard, R. W., Thorner, P. S., Chan, H. S., Griffiths, A. M., and Cutz, E. (1990) Pediatr. Pathol. 10, 581-592[Medline] [Order article via Infotrieve]
40. Dammrich, J., Ormanns, W., and Schaffer, R. (1984) Histochemistry 81, 369-372[Medline] [Order article via Infotrieve]
41. DeLellis, R. A., Nunnemacher, G., Bitman, W. R., Gagel, R. F., Tashjian, A. H., Jr., Blount, M., and Wolfe, H. J. (1979) Lab. Invest. 40, 140-154[Medline] [Order article via Infotrieve]
42. Silver, M. M., Hearn, S. A., Lines, L. D., and Troster, M. (1988) J. Histochem. Cytochem. 36, 1031-1036[Abstract]
43. Sletten, K., Westermark, P., and Natvig, J. B. (1976) J. Exp. Med. 143, 993-998[Abstract]
44. Schubert, D., Behl, C., Lesley, R., Brack, A., Dargusch, R., Sagara, Y., and Kimura, H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1989-1993[Abstract]
45. Liu, Y., and Schubert, D. (1997) J. Neurochem. 69, 2285-2293[Medline] [Order article via Infotrieve]
46. Koo, E. H., Lansbury, P. T., Jr., and Kelly, J. W. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 9989-9990[Free Full Text]
47. Gorevic, P. D., Castano, E. M., Sarma, R., and Frangione, B. (1987) Biochem. Biophys. Res. Commun. 147, 854-862[Medline] [Order article via Infotrieve]
48. Shen, C. L., Fitzgerald, M. C., and Murphy, R. M. (1994) Biophys. J. 67, 1238-1246[Abstract]
49. Shen, C. L., and Murphy, R. M. (1995) Biophys. J. 69, 640-651[Abstract]
50. Whitson, J. S., Mims, M. P., Strittmatter, W. J., Yamaki, T., Morrisett, J. D., and Appel, S. H. (1994) Biochem. Biophys. Res. Commun. 199, 163-170[CrossRef][Medline] [Order article via Infotrieve]
51. Chang, C. T., Wu, C. S., and Yang, J. T. (1978) Anal. Biochem. 91, 13-31[Medline] [Order article via Infotrieve]
52. Klunk, W. E., Pettegrew, J. W., and Abraham, D. J. (1989) J. Histochem. Cytochem. 37, 1293-1297[Abstract]
53. Klunk, W. E., Pettegrew, J. W., and Abraham, D. J. (1989) J. Histochem. Cytochem. 37, 1273-1281[Abstract]
54. Seifert, R., and Schultz, G. (1987) Biochem. Biophys. Res. Commun. 146, 1296-1302[Medline] [Order article via Infotrieve]
55. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Anal. Biochem. 150, 76-85[Medline] [Order article via Infotrieve]
56. Cassel, D., and Selinger, Z. (1976) Biochim. Biophys. Acta 452, 538-551[Medline] [Order article via Infotrieve]
57. Aktories, K., Schultz, G., and Jakobs, K. H. (1983) Naunyn-Schmiedeberg's Arch. Pharmacol. 324, 196-200[Medline] [Order article via Infotrieve]
58. Brouillet, E., Trembleau, A., Galanaud, D., Volovitch, M., Bouillot, C., Valenza, C., Prochiantz, A., and Allinquant, B. (1999) J. Neurosci. 19, 1717-1727[Abstract/Free Full Text]
59. Klinker, J. F., Lichtenberg-Kraag, B., Damm, H., and Rommelspacher, H. (1996) Neurosci. Lett. 213, 25-28[CrossRef][Medline] [Order article via Infotrieve]
60. Offermanns, S., Schultz, G., and Rosenthal, W. (1989) Eur. J. Biochem. 180, 283-287[Abstract]
61. Lazari, M. F., Porto, C. S., Freymuller, E., Abreu, L. C., and Picarelli, Z. P. (1997) Biochem. Pharmacol. 54, 399-408[CrossRef][Medline] [Order article via Infotrieve]
62. Dorland, R. B., Middlebrook, J. L., and Leppla, S. H. (1979) J. Biol. Chem. 254, 11337-11342[Abstract]
63. Trop, M., and Birk, Y. (1970) Biochem. J. 116, 19-25[Medline] [Order article via Infotrieve]
64. Pollack, S. J., Sadler, I. I., Hawtin, S. R., Tailor, V. J., and Shearman, M. S. (1995) Neurosci. Lett. 184, 113-116[CrossRef][Medline] [Order article via Infotrieve]
65. Pedersen, S. E., and Ross, E. M. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 7228-7232[Abstract]
66. Burch, R. M., and Axelrod, J. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 6374-6378[Abstract]
67. Butler, S. J., Kelly, E. C., McKenzie, F. R., Guild, S. B., Wakelam, M. J., and Milligan, G. (1988) Biochem. J. 251, 201-205[Medline] [Order article via Infotrieve]
68. Eckstein, F., Cassel, D., Levkovitz, H., Lowe, M., and Selinger, Z. (1979) J. Biol. Chem. 254, 9829-9834[Medline] [Order article via Infotrieve]
69. Freissmuth, M., Boehm, S., Beindl, W., Nickel, P., Ijzerman, A. P., Hohenegger, M., and Nanoff, C. (1996) Mol. Pharmacol. 49, 602-611[Abstract]
70. Freissmuth, M., Waldhoer, M., Bofill-Cardona, E., and Nanoff, C. (1999) Trends Pharmacol. Sci. 20, 237-245[CrossRef][Medline] [Order article via Infotrieve]
71. Gilman, A. G. (1987) Annu. Rev. Biochem. 56, 615-649[CrossRef][Medline] [Order article via Infotrieve]
72. Huang, R. R., Dehaven, R. N., Cheung, A. H., Diehl, R. E., Dixon, R. A., and Strader, C. D. (1990) Mol. Pharmacol. 37, 304-310[Abstract]
73. Silk, S. T., Clejan, S., and Witkom, K. (1989) J. Biol. Chem. 264, 21466-21469[Abstract/Free Full Text]
74. Birnbaumer, L. (1990) Annu. Rev. Pharmacol. Toxicol. 30, 675-705[CrossRef][Medline] [Order article via Infotrieve]
75. Bokoch, G. M., Katada, T., Northup, J. K., Hewlett, E. L., and Gilman, A. G. (1983) J. Biol. Chem. 258, 2072-2075[Abstract/Free Full Text]
76. Bokoch, G. M., Katada, T., Northup, J. K., Ui, M., and Gilman, A. G. (1984) J. Biol. Chem. 259, 3560-3567[Abstract/Free Full Text]
77. Jones, D. T., and Reed, R. R. (1987) J. Biol. Chem. 262, 14241-14249[Abstract/Free Full Text]
78. Jones, D. T., Masters, S. B., Bourne, H. R., and Reed, R. R. (1990) J. Biol. Chem. 265, 2671-2676[Abstract/Free Full Text]
79. Cribbs, D. H., Pike, C. J., Weinstein, S. L., Velazquez, P., and Cotman, C. W. (1997) J. Biol. Chem. 272, 7431-7436[Abstract/Free Full Text]
80. Pallitto, M. M., Ghanta, J., Heinzelman, P., Kiessling, L. L., and Murphy, R. M. (1999) Biochemistry 38, 3570-3578[CrossRef][Medline] [Order article via Infotrieve]
81. Ghanta, J., Shen, C. L., Kiessling, L. L., and Murphy, R. M. (1996) J. Biol. Chem. 271, 29525-29528[Abstract/Free Full Text]
82. Soomets, U., Mahlapuu, R., Tehranian, R., Jarvet, J., Karelson, E., Zilmer, M., Iverfeldt, K., Zorko, M., Graslund, A., and Langel, U. (1999) Brain Res. 850, 179-188[CrossRef][Medline] [Order article via Infotrieve]
83. Singh, I. N., Sorrentino, G., Sitar, D. S., and Kanfer, J. N. (1998) Brain Res. 800, 275-281[CrossRef][Medline] [Order article via Infotrieve]
84. Schnecko, A., Witte, K., Bohl, J., Ohm, T., and Lemmer, B. (1994) Brain Res. 644, 291-296[Medline] [Order article via Infotrieve]
85. Brorson, J. R., Bindokas, V. P., Iwama, T., Marcuccilli, C. J., Chisholm, J. C., and Miller, R. J. (1995) J. Neurobiol. 26, 325-338[Medline] [Order article via Infotrieve]
86. Mattson, M. P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., and Rydel, R. E. (1992) J. Neurosci. 12, 376-389[Abstract]
87. Davidson, R. M., Shajenko, L., and Donta, T. S. (1994) Brain Res. 643, 324-327[Medline] [Order article via Infotrieve]
88. Li, W. Y., Czilli, D. L., and Simmons, L. K. (1995) Brain Res. 682, 207-211[CrossRef][Medline] [Order article via Infotrieve]
89. Birnbaumer, L., Yatani, A., VanDongen, A. M., Graf, R., Codina, J., Okabe, K., Mattera, R., and Brown, A. M. (1990) Soc. Gen. Physiol. Ser. 45, 169-183[Medline] [Order article via Infotrieve]
90. Brown, A. M., Yatani, A., Codina, J., and Birnbaumer, L. (1990) Prog. Clin. Biol. Res. 334, 303-312[Medline] [Order article via Infotrieve]
91. Hescheler, J., Rosenthal, W., Trautwein, W., and Schultz, G. (1987) Nature 325, 445-447[CrossRef][Medline] [Order article via Infotrieve]
92. Spiegel, A. M., Shenker, A., and Weinstein, L. S. (1992) Endocr. Rev. 13, 536-565[Medline] [Order article via Infotrieve]
93. Schultz, G., Rosenthal, W., Hescheler, J., and Trautwein, W. (1990) Annu. Rev. Physiol. 52, 275-292[CrossRef][Medline] [Order article via Infotrieve]
94. Birnbaumer, L., Abramowitz, J., and Brown, A. M. (1990) Biochim. Biophys. Acta 1031, 163-224[Medline] [Order article via Infotrieve]
95. Brown, A. M., and Birnbaumer, L. (1990) Annu. Rev. Physiol. 52, 197-213[CrossRef][Medline] [Order article via Infotrieve]
96. Simon, M. I., Strathmann, M. P., and Gautam, N. (1991) Science 252, 802-808[Medline] [Order article via Infotrieve]
97. Higashijima, T., Uzu, S., Nakajima, T., and Ross, E. M. (1988) J. Biol. Chem. 263, 6491-6494[Abstract/Free Full Text]
98. Gudi, S. R., Clark, C. B., and Frangos, J. A. (1996) Circ. Res. 79, 834-839[Abstract/Free Full Text]
99. Berthiaume, F., and Frangos, J. A. (1994) Biochim. Biophys. Acta 1191, 209-218[Medline] [Order article via Infotrieve]
100. Choo-Smith, L. P., Garzon-Rodriguez, W., Glabe, C. G., and Surewicz, W. K. (1997) J. Biol. Chem. 272, 22987-22990[Abstract/Free Full Text]
101. Choo-Smith, L. P., and Surewicz, W. K. (1997) FEBS Lett. 402, 95-98[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.